A tractor-trailer crash early Wednesday led to lane reductions and periodic road closures along U.S. Route 2 in Gilead, ...
Gilead Sciences Inc. (NASDAQ:GILD) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the ...
A Gilead Sciences executive who left the San Fransisco pharmaceutical giant last month after nearly four years, has been ...
AbbVie and Gilead Sciences each used the holiday season to reward their pipelines with a new clinical-stage cancer drug. | ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best affordable healthcare stocks to buy now. Gilead Sciences, Inc. (NASDAQ ...
Gilead Sciences’ chief medical officer will leave the company early next year as the drugmaker struggles to find new areas of growth beyond its core portfolio of HIV medicines. Merdad Parsey, who ...
Two years after Gilead Sciences secured the first option on Assembly Biosciences’ entire pipeline, the pharma has decided to ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor ...
GlobalData on MSN
Gilead Sciences to acquire Repare’s RP-3467
Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.
Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since he took the reins in 2019. O’Day received a compensation package of $23.7 ...
Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which said ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback